---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-040611"
form_type: "8-K"
ticker: "SRZN"
cik: "0001824893"
company_name: "Surrozen, Inc./DE"
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T23:12:58.613824+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Surrozen Q2 net loss $9.4M; cash runway extended into 2025 on prioritization

## Summary
- Net loss of $9.4M improved from $13.9M YoY; cash and securities $53.4M (down from $61.7M in Q1).
- R&D expenses fell to $6.9M from $9.6M YoY; G&A expenses to $3.3M from $4.5M YoY.
- SZN-043 Phase 1a enrollment continues; safety data expected by end of 2023; Phase 1b in alcoholic hepatitis planned for 2024.
- SZN-1326 Phase 1a enrollment continues; Phase 1b in ulcerative colitis planned for 2024, proof-of-concept data expected H2 2024.
- Boehringer Ingelheim partnership may trigger $10M milestone in 2024 upon Fzd-4 candidate nomination.

## SEC filing metadata
- accession: 0000950170-23-040611
- form_type: 8-K
- ticker: SRZN
- cik: 0001824893
- company_name: Surrozen, Inc./DE
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824893/000095017023040611/0000950170-23-040611-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824893/000095017023040611/srzn-20230809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-040611
- JSON: https://secwatch.observer/filing/0000950170-23-040611.json
- Plain text: https://secwatch.observer/filing/0000950170-23-040611.txt

## Key facts
- Earnings Releases
  Surrozen, Inc./DE reported second quarter ended June 30, 2023 results: net income Net loss for the second quarter ended June 30, 2023 was $9.4 million, as compared to $13.9 million for the same period i.
  - Period: second quarter ended June 30, 2023
  - Net income: Net loss for the second quarter ended June 30, 2023 was $9.4 million, as compared to $13.9 million for the same period i
  - Result: reported results
  source text: Net loss for the second quarter ended June 30, 2023 was $9.4 million, as compared to $13.9 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1824893/000095017023040611/0000950170-23-040611-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.